Liquid biopsy resources on SlideShare

SlideShare_LabBench_LiquidBiopsy_700x233

QIAGEN offers a complete, efficient and streamlined workflow to empower your liquid biopsy research. We have added our newest webinar presentations and videos covering circulating cell-free DNA, circulating tumor cells and exosomes to SlideShare. Whether you want to learn how to collect and stabilize blood samples, discover a complete and efficient workflow for ccfDNA analysis, detect and characterize CTCs from blood samples, or learn how to enrich and isolate exosomes and exosomal RNA, we have a resource to help you in your research journey.

PreAnalytiX, a QIAGEN joint venture with BD, has developed the PAXgene Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube and the QIAsymphony PAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 4.8 ml plasma. This slide deck presents this new technology development and a streamlined workflow for integrated collection, stabilization and purification of circulating cell-free DNA from whole blood.

Looking for an automated and standardized process to isolate circulating cell-free DNA? This slide deck features an optimized process for efficient ccfDNA enrichment and extraction from plasma samples, and presents a novel automated extraction of ccfDNA using the QIAsymphony SP instrument for liquid biopsy diagnostic applications.

Are you struggling with ccfDNA library yields and accuracy of your NGS results? This slide deck introduces new technical solutions for Ion Torrent and Illumina sequencing platforms that combine optimized ccfDNA isolation, highly advanced library construction, unbiased library amplification and integrated data analysis to reliably analyze ccfDNA samples with high sensitivity.

CTCs are very rare and highly heterogeneous. In addition, during the epithelial-mesenchymal transition (EMT) process, CTCs lose their epithelial characteristics and acquire more mesenchymal-like phenotypes, which pose an additional challenge for CTC detection and characterization. In this slide deck, Dr. Siegfried Hauch introduces the AdnaTests, which use the Combination of Combinations Principle (COCP) to enable enrichment and detection of CTCs in whole blood with high specificity and sensitivity.

Epithelial ovarian cancer ranks as the second most common type of gynecological malignancy and has poor survival rates. In this presentation, Dr. Sabine Kasimir-Bauer from the University of Duisburg-Essen demonstrates that the negative prognostic impact of CTCs and disseminated tumor cells (DTCs) arise from specific cellular phenotypes and are associated with platinum-based resistance and stem cell-associated proteins.

This slide deck gives an overview of the recent progress in exploring the diagnostic, prognostic and predictive potential of circulating biomarkers, including circulating tumor cells, circulating tumor DNA, miRNAs, lncRNAs and exosomes. Addressing both biological and technical aspects, we discuss the isolation and characterization of circulating biomarkers, as well as challenges and solutions.


NGS for liquid biopsy research – download the flyer

Next-generation sequencing (NGS) is being utilized for numerous new and exciting applications, such as single cell analysis, liquid biopsy research and circulating cell-free DNA (cfDNA) studies. QIAGEN is offering integrated Sample to Insight solutions for liquid biopsy research based on a highly efficient and sensitive NGS analysis system. Download this flyer, “NGS for liquid biopsy research,” and explore new frontiers with NGS!

Download the flyer!

Interested in learning more about QIAGEN’s liquid biopsy research solutions? Check out our liquid biopsy portal!

Wei Cao, Ph.D.

Senior Global Marketing Manager, Translational Sciences

Dr. Wei Cao joined QIAGEN in 2010 and currently leads the webinar program, presenting various topics on advanced techniques in biomedical research. She received her Ph.D. from Peking University in China in 2010, and conducted postdoctoral research at Weill Cornell Medical College in New York City. Before joining QIAGEN, Dr. Cao worked as a senior scientist in R&D in pharmaceutical and biotech, focusing on HIV, HCV and cancer drug discovery and development.

Your email address will not be published. Required fields are marked *